Volume 28, Number 7—July 2022
Dispatch
Multisystem Inflammatory Syndrome after Breakthrough SARS-CoV-2 Infection in 2 Immunized Adolescents, United States
Table 1
Result† | Case-patient 1, hospitalization for MIS-C |
Case-patient 2‡ |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre–MIS-C hospitalization |
Hospitalization for MIS-C |
||||||||||||||
HD1 | HD2 | HD3 | HD4 | HD5 | HD6 | HD1 | HD4 | HD1 | HD3 | HD5 | HD7 | HD9 | |||
Leukocytes, × 109 cells/L |
↓3.6 |
↓4.1 |
↓2.3 |
↓2.6 |
↓3.1 |
↓2.7 |
11.9 |
NA |
7.8 |
5.8 |
↓2.9 |
5.4 |
9.0 |
||
Hemoglobin, g/dL |
12.5 |
13.1 |
12.4 |
12.2 |
12.4 |
↓10.5 |
13.5 |
NA |
13.8 |
↓10.8 |
↓10.4 |
↓10.3 |
↓10.5 |
||
Platelets, 109/L |
↓98 |
↓109 |
188 |
237 |
321 |
362 |
290 |
NA |
373 |
265 |
NA |
305 |
331 |
||
Absolute neutrophil count, × 109 cells/L |
2.4 |
3.3 |
↓1 |
↓0.9 |
↓1 |
↓0.6 |
NA |
NA |
↓1.4 |
1.8 |
2.0 |
3.6 |
4.7 |
||
Absolute lymphocyte count, × 109 cells/L |
1 |
↓0.6 |
1.1 |
1.3 |
1.7 |
1.8 |
NA |
NA |
5.8 |
2.3 |
↓0.6 |
1.2 |
2.8 |
||
ESR, mm/h |
NA |
6 |
7 |
↑23 |
↑24 |
↑25 |
↑18 |
NA |
↑22 |
↑96 |
NA |
NA |
NA |
||
Sodium, mmol/L |
↓130 |
↓136 |
↓134 |
↓133 |
↓132 |
137 |
↓135 |
NA |
↓136 |
137 |
↓127 |
↓136 |
139 |
||
Creatinine, mg/dL |
↑1.2 |
↑1.0 |
↑0.9 |
0.7 |
↑0.8 |
0.6 |
0.7 |
NA |
↑1.0 |
↑2.2 |
↑3.9 |
↑2.3 |
↑1.3 |
||
AST, U/L |
↑165 |
↑207 |
↑131 |
↑114 |
↑200 |
↑164 |
↑297 |
↑164 |
↑102 |
↑169 |
↑53 |
28 |
33 |
||
ALT, U/L |
↑221 |
↑243 |
↑196 |
↑167 |
↑195 |
↑162 |
↑249 |
↑269 |
↑188 |
↑177 |
↑123 |
↑57 |
45 |
||
GGT, U/L |
↑126 |
↑137 |
↑129 |
↑128 |
↑136 |
NA |
NA |
NA |
↑342 |
↑209 |
NA |
NA |
NA |
||
LDH, U/L |
↑1,484 |
NA |
↑1,155 |
↑928 |
↑863 |
NA |
↑1,313 |
NA |
↑982 |
NA |
NA |
NA |
NA |
||
C-reactive protein, mg/L |
↑135 |
↑86 |
↑64 |
↑36 |
↑19 |
↑11 |
↑23 |
NA |
↑17 |
↑47 |
↑56 |
↑19 |
10 |
||
Ferritin, ng/mL |
↑750 |
NA |
↑576 |
↑626 |
↑754 |
↑578 |
↑593 |
NA |
191 |
284 |
NA |
NA |
NA |
||
Albumin, g/dL |
NA |
↓2.9 |
↓2.8 |
↓2.8 |
↓3.1 |
↓3.1 |
↓3.1 |
↓3.2 |
3.6 |
↓2.6 |
3.0 |
↓3.1 |
↓3.1 |
||
aPTT, s |
↑42.9 |
36.5 |
↑38.9 |
↑39.4 |
NA |
NA |
↓20.5 |
NA |
28.9 |
31.3 |
NA |
NA |
NA |
||
PT, s |
14 |
12.6 |
13.5 |
13.7 |
14.1 |
13.5 |
13.4 |
NA |
13.5 |
14.7 |
NA |
NA |
NA |
||
Fibrinogen, mg/dL |
328 |
354 |
302 |
269 |
317 |
NA |
258 |
NA |
413 |
NA |
NA |
NA |
NA |
||
D-dimer, μg/mL |
NA |
↑>4 |
↑>4 |
↑>4 |
↑3.1 |
NA |
NA |
NA |
↑2.8 |
NA |
NA |
NA |
NA |
||
Troponin-I, ng/mL |
0.03 |
↑0.04 |
↑0.05 |
0.03 |
0.02 |
NA |
<0.02 |
NA |
<0.02 |
NA |
NA |
NA |
NA |
||
NT-proBNP, pg/mL | ↑365 | ↑477 | ↑601 | ↑1,020 | ↑212 | NA | 66 | NA | 85 | ↑3,190 | ↑3,360 | ↑1,300 | ↑1,590 |
*ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transpeptidase; HD, hospital day; LDH, lactate dehydrogenase; MIS-C, multisystem inflammatory syndrome in children; NT-proBNP, N-type pro-brain natriuretic peptide; PT, prothrombin time; ↑, increased outside of reference range; ↓, decreased outside of reference range. †Reference ranges: leukocytes, 5.2–9.7 × 109 cells/L; hemoglobin, 11.8–15.8 g/dL; platelets, 150–500 × 109/L; absolute neutrophil count, 1.8–6.6 × 109 cells/L; absolute lymphocyte count, 1.0–4.8 × 109/L; ESR, <15 mm/h; sodium, 137–145 mmol/L; creatinine, 0.2–0.7 mg/dL; AST, 15–40 U/L; ALT, <50 U/L; GGT, 10–28 U/L; LDH, 360–730 U/L; C-reactive protein, 0–10 mg/L; ferritin, 6–464 ng/mL; albumin 3.5–5 g/dL; aPTT, 23.5–37.5 s; PT, 11.5–15.0 s; fibrinogen, 200–450 mg/dL; D-dimer, <0.5 μg/mL; troponin-I, <0.03 ng/mL; NT-proBNP, <125 pg/mL ‡Omitted data for case-patient 2 from HD2 and HD3 of pre–MIS-C hospitalization and data from HD4, HD6, and HD8 of hospitalization for MIS-C were unnecessary for demonstrating clinical trends